NEW YORK (GenomeWeb News) – MDS today reported that its second-quarter revenues fell 21 percent and it swung to a loss from a profit year over year as soft spending markets took a toll on its top and bottom lines.

The Toronto-based firm brought in total revenues of $282 million for the three-month period ended April 30, compared to revenues of $350 million for the second quarter of 2008. It said that excluding the impact of foreign exchange, acquisitions, and divestitures its net revenue decreased 10 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.